This allowed Regeneron and Teva to continue with trials on fasinumab, and Pfizer and Eli Lilly to resume trials into tanezumab. The latest results from Regeneron and Teva are from a sub-study in a ...

The drug was first approved in the 1990s and is currently marketed by Eli Lilly under the brand name Zyprexa. Teva, which launched a Dr. Reddy’s-partnered generic to Zyprexa in 2011, spotted a ...

Eli Lilly partners with VC to launch 700 billion won biotech ecosystem fund Eli Lilly collaborates with a16z to create a vast ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

CGRP Inhibitors Market. The global CGRP inhibitors market is poised for robust growth, with its valuation expected to rise ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...